ExpreS2ion Biotech Holding AB announced that Dr. Mattis Ranthe, Chief Medical Officer, and Dr. Mette Thorn, Senior Vice President of Preclinical Development, are stepping down from their positions in the Company following the future strategic focus on ExpreS2ion's exploratory vaccine pipeline and technology platforms, as announced on 17 August 2023. Dr. Ranthe will continue supporting the Company through the end of 2023 to ensure the transition of his responsibilities. Dr. Thorn's last day is 29 September 2023, and her responsibilities will be covered by internal resources.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.6 SEK | -5.11% | -6.47% | +23.22% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+23.22% | 12.85M | |
-3.70% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-14.82% | 15.36B | |
-8.82% | 11.95B | |
-16.29% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.60% | 8.12B |
- Stock Market
- Equities
- EXPRS2 Stock
- News ExpreS2ion Biotech Holding AB
- ExpreS2ion Biotech Holding AB Announces Changes to Leadership Team